Gene Therapies, IPO Surges, and FDA Shifts
Kilder
- Genengnews: Gene Therapy Briefs: Regeneron Wins FDA Approval for First Neurosensory Gene Therapy - Genetic Engineering and Biotechnology News
- genengnews.com: Gene Therapy Briefs: Regeneron Wins FDA Approval for First Neurosensory Gene Therapy - Genetic Engineering and Biotechnology News
- genengnews.com: ParcelBio Unveils Programmable mRNA Platform Backed by $13M Financing - Genetic Engineering and Biotechnology News
- genengnews.com: ASGCT Honors Mohamed Abou‑el‑Enein as Outstanding New Investigator - Genetic Engineering and Biotechnology News
- Bioworld: In vivo mRNA gene therapy platform reprograms cytotoxic T cells - BioWorld News
- bioworld.com: In vivo mRNA gene therapy platform reprograms cytotoxic T cells - BioWorld News
- bioworld.com: Two-step HIV vaccine induces broadly neutralizing antibodies - BioWorld News
- Fiercebiotech: A protective gene sent to the liver cleared amyloid from mouse brains, sparking hope for an Alzheimer’s gene therapy - Fierce Biotech
- fiercebiotech.com: A protective gene sent to the liver cleared amyloid from mouse brains, sparking hope for an Alzheimer’s gene therapy - Fierce Biotech
- Labiotech: The biggest biotech funding rounds in April 2026 - Labiotech.eu
- labiotech.eu: The biggest biotech funding rounds in April 2026 - Labiotech.eu
- biospace.com: Mobia Medical Announces Pricing of Initial Public Offering - BioSpace
- bioworld.com: Mobia debuts on Nasdaq to bring stroke therapy to more patients - BioWorld News
- Statnews: Why we left the FDA: Six former officials share their stories - statnews.com
- statnews.com: Why we left the FDA: Six former officials share their stories - statnews.com
- geneonline.com: Six Former FDA Officials’ Departures Detailed in May 8, 2026, STATus Report - geneonline.com
- statnews.com: What was lost at the FDA - statnews.com
- wikimedia: Photo by NIAID / Wikimedia Commons / CC BY 2.0
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.